Literature DB >> 18045110

Roles of HIV-1 Env variable regions in viral neutralization and vaccine development.

Abraham Pinter1.   

Abstract

A major focus of HIV-1 vaccine development has been directed towards a limited number of broadly conserved epitopes in the Envelope (Env) proteins that are sensitive neutralization targets in many primary isolates. However, evidence suggests that these epitopes are poorly immunogenic; similar antibodies are rarely produced by infected subjects, nor are they induced by various immunogens designed to express these epitopes. On the other hand, the major variable domains of Env are highly immunogenic; antibodies against these regions are common in sera of infected patients and easily generated upon immunization. Although these epitopes are extremely sensitive neutralization targets in some laboratory strains and primary isolates, the neutralization range of antibodies against these sites is limited. This review describes potent neutralization epitopes located in the variable regions of Env and discusses the bases for the limited neutralization breadth of antibodies against these targets. Strategies are discussed for using available information to design immunogens capable of exploiting the potential of these regions as vaccine targets.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18045110     DOI: 10.2174/157016207782418470

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  24 in total

1.  Conserved structural elements in the V3 crown of HIV-1 gp120.

Authors:  Xunqing Jiang; Valicia Burke; Maxim Totrov; Constance Williams; Timothy Cardozo; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  Nat Struct Mol Biol       Date:  2010-07-11       Impact factor: 15.369

2.  Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities.

Authors:  Chavdar Krachmarov; Zhong Lai; William J Honnen; Aidy Salomon; Miroslaw K Gorny; Susan Zolla-Pazner; James Robinson; Abraham Pinter
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

3.  Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.

Authors:  Sara M O'Rourke; Becky Schweighardt; Pham Phung; Kathryn A Mesa; Aaron L Vollrath; Gwen P Tatsuno; Briana To; Faruk Sinangil; Kay Limoli; Terri Wrin; Phillip W Berman
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

4.  Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV.

Authors:  Brett Spurrier; Jared Sampson; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

Review 5.  Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases.

Authors:  M L Bellows; C A Floudas
Journal:  Curr Drug Targets       Date:  2010-03       Impact factor: 3.465

6.  Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum.

Authors:  Marit J van Gils; Diana Edo-Matas; Emma J Bowles; Judith A Burger; Guillaume B Stewart-Jones; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-06-08       Impact factor: 5.103

7.  HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.

Authors:  Susan M Schader; Susan P Colby-Germinario; Peter K Quashie; Maureen Oliveira; Ruxandra-Ilinca Ibanescu; Daniela Moisi; Thibault Mespléde; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

8.  Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer.

Authors:  Li Liu; Raffaello Cimbro; Paolo Lusso; Edward A Berger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-29       Impact factor: 11.205

9.  High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Authors:  Katie L Davis; Elin S Gray; Penny L Moore; Julie M Decker; Aidy Salomon; David C Montefiori; Barney S Graham; Michael C Keefer; Abraham Pinter; Lynn Morris; Beatrice H Hahn; George M Shaw
Journal:  Virology       Date:  2009-03-18       Impact factor: 3.616

10.  Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects.

Authors:  Filippo Canducci; Maria Chiara Marinozzi; Michela Sampaolo; Stefano Berrè; Patrizia Bagnarelli; Massimo Degano; Giulia Gallotta; Benedetta Mazzi; Philippe Lemey; Roberto Burioni; Massimo Clementi
Journal:  Retrovirology       Date:  2009-01-15       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.